Ludwig In the News

November 29, 2023
X-Health show

Ludwig Lausanne Director George Coukos was the featured guest on this podcast, which focuses on the future of healthcare.

November 28, 2023

This article covers talks given by Ludwig Oxford’s Richard White and Ludwig MIT Co-director Tyler Jacks at the Barcelona Biomed conference. Free registration is required for full access to this article.

November 9, 2023

Ludwig Princeton’s Michael Skinnider won the grand prize of the NOMIS & Science Young Explorer Award for this essay, which describes his development as an MD/PhD student of an AI technology to detect novel designer drugs as they emerge on the illicit market.

October 15, 2023

This article profiles Ludwig Institute Board Member Jedd Wolchok, who was recently elected to the National Academy of Medicine in recognition of his landmark contributions to tumor immunology and immunotherapy.

September 1, 2023
JCO Precision Oncology

Ludwig Johns Hopkins’ Yuxuan Wang and Ludwig alumnus Jeanne Tie of the University of Melbourne discuss in this editorial the current state of liquid biopsy clinical development as well as a prospective study reported in the same issue of the journal examining the use of one such test in a subgroup of symptomatic participants.

August 21, 2023
The Miror

This story reports on a multiplexed nanotech diagnostic that can not only detect cancer but also discriminate between tumor types and states of disease progression developed by Ludwig MIT’s Sangeeta Bhatia and colleagues and reported in Nature Nanotechnology, which eLudwigNews covered in April.

July 10, 2023
Cancer Discovery*

An interview with Ludwig Institute Scientific Advisor Philip Greenberg, who began a one-year term as president of the American Association for Cancer Research in April 2023.

June 20, 2023
Science Signaling

A Nature paper led by Ludwig Institute’s Benoît Van den Eynde and Jingjing Zhu reporting that existing antihypertensive drugs, α2AR agonists, can potently activate antitumor immune responses is discussed in this Editors’ Choice article.

June 13, 2023
The ASCO Post

This article covers a Nature study co-led by Ludwig Harvard’s Andrew Lane and Peter van Galen on how the journey of precancerous cells from the bone marrow to the skin can trigger genetic transformations that initiate a rare type of leukemia.

June 3, 2023
The ASCO Post

This profile of George Demetri covers the Ludwig Harvard co-director’s life, education, hobbies and fascinations, along with his outsize contributions to cancer research and care.

May 16, 2023

This article highlights the pioneering work done by Ludwig Harvard’s Rakesh Jain on the normalization of tumor blood vessels induced by angiogenesis inhibitors.

April 27, 2023
MedCity News

Quest Diagnostics is acquiring Haystack Oncology, which was founded by Ludwig Johns Hopkins’ Bert Vogelstein, Ken Kinzler and Nick Papadopoulos. The development of its technology was supported in good measure by a program for cancer prevention launched by Ludwig Cancer Research and the Conrad N. Hilton Foundation.

Additional coverage: The Business Journals* | GenomeWeb | MedTech Dive | STAT*| MedTech Insight | FierceBiotech | NJ Biz

April 20, 2023

This article shares new discoveries and presentations at the AACR 2023 Annual Meeting, including a presentation by Ludwig Stanford’s Siddhartha Jaiswal on CHIP, a disorder driven by the accumulation of somatic mutations in stem cells that can give rise to blood cancers and is associated with a number of other diseases.

April 13, 2023

In this article, Cell asked researchers, including Ludwig Lausanne’s Johanna Joyce and Ludwig Institute Scientific Advisor Juanita Merchant, about the questions they believe to be most important to the advancement of cancer research and care.

April 5, 2023
The Korea Herald

Ludwig Harvard’s Marcia Haigis was among the winners of the Samsung Ho-Am Prize award for this year in the fields of science, engineering, medicine, arts and community service.

March 30, 2023
News Medical

This study, led by Ludwig Lausanne Member Mikaël Pittet and Allon Klein of Harvard Medical School, identifies a functional state assumed by neutrophils following immunotherapy—termed the Sellhi state—in which they become formidable agents of antitumor immunity in mouse models of lung and colon cancer.


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?